

BONESUPPORT's CERAMENT®G used in first U.S. patient cases

BONESUPPORT, an emerging leader in orthobiologics for the management of bone injuries, today announces that the company's antibiotic-eluting bone graft CERAMENT G (Gentamicin) has been used surgically for the first time in patients in the US. The patients treated had bone infection (osteomyelitis) caused by fractures induced by trauma.

"CERAMENT G is truly changing the way we can treat osteomyelitis by more directly and effectively addressing the site of the infection in a single stage, patient friendly surgical approach. CERAMENT G has been widely used with great success in other parts of the world and I'm pleased to integrate it in my clinical practice," said Janet D. Conway, MD, FAAOS, board-certified orthopedic surgeon and Head of Bone and Joint Infection at Sinai Hospital of Baltimore, who carried out the first surgeries using CERAMENT G in the US.

BONESUPPORT received **authorization** for CERAMENT G in the management of osteomyelitis from the US Food and Drug Administration (FDA) earlier this year. The extensive clinical documentation on which the market approval is based, shows that CERAMENT G reduces the risk of recurrent bone infection to 4.3–5.5 percent versus 13.3 percent for the current US standard of care, PMMA-beads. CERAMENT G is the first and only FDA authorized combination antibiotic-eluting bone graft.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
24 October 2022 14:00:00 CEST



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

[BONESUPPORT's CERAMENT®G used in first U.S. patient cases](#)